US › Healthcare

BeiGene, Ltd. (ONC)

US · Healthcare · Biotechnology

$323.01+2.94%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.51B
Revenue YoY
+35.5%
Net profit
$227.4M
Profit YoY
+17802.1%
EPS
$1.96
EPS estimate
$0.81
Net margin
15.0%

EPS came in at 1.96 against a street estimate of 0.81 — a beat of 142.0%.

Key statistics

Market cap
$32.55B
P/E
71.0
Forward P/E
47.8
P/B
6.89
Book value
$42.84
EPS (TTM)
$4.42
52-week high
$385.22
52-week low
$253.95
50-day MA
$294.51
200-day MA
$314.02
Beta
0.50

Analyst view

Analysts rate BeiGene, Ltd. a strong buy (23 buy, 1 hold, 0 sell out of 24) with an average price target of $415.64.

Shareholding

Insiders
17.29%
Institutions
33.02%

Largest institutional holders

FundStake
Baker Bros Advisors LP7.91%
PRIMECAP Management Company4.47%
Capital Research & Mgmt Co - Division 33.74%
FMR Inc3.32%
Capital World Investors1.46%
Hillhouse Capital Advisors, Ltd.0.93%
Citadel Advisors Llc0.93%
Temasek Holdings Ltd.0.78%

Recent filings & reports

DocumentDate
Company announcement · Q2 20262026-06-26
Board / officer change · Q2 20262026-06-11
Company announcement · Q2 20262026-05-15
Quarterly report · Q1 20262026-05-06
Results announced · Q2 20262026-05-06
Proxy statement · Q2 20262026-04-28
Annual report FY20252026-02-26
Quarterly report · Q3 20252025-11-06

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BeiGene, Ltd. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.